Research from University of Michigan reveals new findings on immunotherapy
2009 JUL 8 - (NewsRx.com) -- "Immunotherapy and vaccination for cancer or infection are generally approached by administration of antigen or stimulation of antigen-presenting cells or both. These measures may fail if the treated individual lacks T cells specific for the immunogen(s)," scientists in the United States report. "We tested another strategy-the generation of new T cells from hematopoietic stem cells that might be used for adoptive immunotherapy. To test this concept, we introduced T cell-depleted human bone marrow cells into fetal swine and tested the swine for human T cells at various times after birth. Human T cells were detected in the thymus and blood of the treated swine. These cells were generated de novo as they contained human T cell receptor excision circles not present in the T cell-depleted bone marrow. The human T cells were highly diverse and included novel specificities capable of responding to antigen presented by human antigen-presenting cells," wrote B.M. Ogle and colleagues, University of Michigan. The researchers concluded: "Our findings constitute a first step in a new promising approach to immunotherapy in which tumor- or virus-specific T cell clones lacking in an individual might be generated in a surrogate host from hematopoietic stem cells of the individual to be treated.." Ogle and colleagues published their study in Tissue Engineering Part a (Toward Development and Production of Human T Cells in Swine for Potential Use in Adoptive T Cell Immunotherapy. Tissue Engineering Part a, 2009;15(5):1031-1040). For more information, contact J.L. Platt, University of Michigan, Biomedical Science Research Bldg, 109 Zina Pitcher Pl, Ann Arbor, MI 48109, USA. Publisher contact information for the journal Tissue Engineering Part a is: Mary Ann Liebert Inc., 140 Huguenot Street, 3RD FL, New Rochelle, NY 10801, USA. Keywords: United States, Ann Arbor, Bioengineering, Biological Therapy, Biomedical Engineering, Biomedicine, Biotechnology, Bone Marrow, Cancer, Hematology, Hematopoietic, Immunization, Immunotherapy, Medical Device, Oncology, Stem Cell Research, Tissue Engineering, Treatment, Vaccination, University of Michigan. This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2009, Vaccine Weekly via NewsRx.com.
|
